St. Louis, Missouri, USA
January 2, 2016
Brian L. Clevinger is a founder and managing director of Prolog Ventures. At Prolog, he has been involved in over 40 investments and served on the board of 10. He has specialized in medical devices, diagnostics, agriculture and animal health. Brian has actively participated in all phases of commercial technology development for nearly three decades. Before Prolog, he was the CEO of Megan Health, a vaccine developer. He held this position from Megan's inception until its acquisition by AVANT Immunotherapeutics. Previously, he was the president of A/W Company, a technology transfer partnership of the private equity firm Alafi Capital and Washington University. Working with Washington University researchers, he evaluated numerous technologies, selected the most commercially promising ones for funding, and served on the board of each resulting enterprise. Before joining A/W Company, he held a tenured position and headed a research laboratory at Washington University. Brian holds a doctoral degree in immunology from Indiana University and was a NIH postdoctoral fellowship at Washington University.
I am very excited to join this team and have experienced nothing but professionalism and strong management during my short tenure thus far. The Yield Lab is uniquely equipped to make very wise investment decisions in early stage AgTech companies. I joined this team at the very beginning of a rigorous diligence process in which we engaged the entire Yield Lab team, our Advisory Team and the companies themselves as we worked through hours and hours of due diligence. I look forward the announcement of our new portfolio in January and working with them in 2016.
The Yield Lab is partnering with BioSTL as the 2016 Yield Lab portfolio is launched this January. BioSTL advances St. Louis’ economic vitality by cultivating a strong bioscience and innovation ecosystem. BioSTL organizes business, university, and philanthropic leaders around a set of deliberate strategies that capitalize on St. Louis’ strengths in medical and plant sciences.
Through its work, BioSTL is helping St. Louis leverage its unique convergence of academic, corporate, and entrepreneurial strengths and continue its growth as the leader in AgTech innovation.
The Yield Lab runs a nine-month program that supports emerging AgTech companies with up to $100,000 in funding, an Agriculture (Ag) specific curriculum, one-on-one mentorship, free workspace, and networking opportunities.
Topics
Species
